CONMED Corporation Announces Third Quarter 2020 Financial Results

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2020.


Third Quarter 2020 Highlights

  • Sales of $237.8 million increased 1.8% year over year as reported and in constant currency.
  • Domestic revenue increased 4.7% year over year.
  • International revenue decreased 1.7% as reported and in constant currency.
  • Diluted net earnings per share (GAAP) was $0.23, which was flat compared to diluted net earnings per share in the third quarter of 2019.
  • Adjusted diluted net earnings per share(1) was $0.88 versus adjusted diluted net earnings per share of $0.62 in the third quarter of 2019.

“Our third quarter results demonstrate our team’s commitment to operational execution in the face of the global COVID-19 environment,” commented Curt R. Hartman, CONMED’s President, Chief Executive Officer and Chair of the Board. “During the quarter, we generated continued positive momentum within our business despite ongoing geographic variability in procedure volumes as a result of pandemic-related disruptions. I remain confident that our team’s outstanding commitment to serving our customers and our continued expense discipline keep us well positioned to achieve profitable above-market growth over the long term.”

2020 Outlook

Due to the continued uncertainty created by the COVID-19 pandemic, management is unable to provide financial guidance at this time.

Supplemental Financial Disclosures

(1) A reconciliation of reported diluted net earnings (loss) per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its third quarter 2020 results.

To participate in the conference call, dial 1-844-889-7792 (domestic) or +1-661-378-9936 (international) and refer to the passcode 2498889.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 7:30 p.m. ET on Wednesday, October 28, 2020, until 7:30 p.m. ET on Wednesday, November 4, 2020. To hear this recording, dial 1-855-859-2056 (domestic) or +1-404-537-3406 (international) and enter the passcode 2498889.

Consolidated Condensed Statements of Income (Loss)

(in thousands, except per share amounts, unaudited)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

 

2020

2019

 

2020

2019

 

 

 

 

 

 

 

Net sales

 

$

237,835

$

233,590

 

$

609,631

$

690,232

Cost of sales

 

 

104,137

 

103,479

 

 

284,845

 

307,492

Gross profit

 

 

133,698

 

130,111

 

 

324,786

 

382,740

% of sales

 

 

56.2%

 

55.7%

 

 

53.3%

 

55.5%

Selling & administrative expense

 

 

94,380

 

98,187

 

 

274,721

 

298,140

Research & development expense

 

 

9,936

 

10,985

 

 

28,756

 

33,366

Income from operations

 

 

29,382

 

20,939

 

 

21,309

 

51,234

% of sales

 

 

12.4%

 

9.0%

 

 

3.5%

 

7.4%

Interest expense

 

 

11,943

 

11,174

 

 

32,938

 

32,382

Other expense

 

 

89

 

321

 

 

266

 

4,867

Income (loss) before income taxes

 

 

17,350

 

9,444

 

 

(11,895)

 

13,985

Provision for income taxes

 

 

10,500

 

2,474

 

 

2,728

 

299

Net income (loss)

 

$

6,850

$

6,970

 

$

(14,623)

$

13,686

 

 

 

 

 

 

 

Basic EPS

 

$

0.24

$

0.25

 

$

(0.51)

$

0.48

Diluted EPS

 

 

0.23

 

0.23

 

 

(0.51)

 

0.47

 

 

 

 

 

 

 

Basic shares

 

 

28,583

 

28,353

 

 

28,529

 

28,280

Diluted shares

 

 

29,426

 

29,792

 

 

28,529

 

29,354

Sales Summary

(in millions, unaudited)

 

Three Months Ended September 30,

 

% Change

 

Domestic

 

International

2020

 

2019

As
Reported

Impact
of
Foreign
Currency

Constant
Currency

 

As
Reported

 

As
Reported

Impact
of
Foreign
Currency

Constant
Currency

Orthopedic Surgery

$

102.2

 

$

110.3

 

-7.4%

0.3%

-7.1%

 

-8.5%

 

-6.7%

0.5%

-6.2%

General Surgery

 

135.6

 

 

123.3

 

10.0%

-0.2%

9.8%

 

11.3%

 

7.3%

-0.9%

6.4%

$

237.8

 

$

233.6

 

1.8%

0.0%

1.8%

 

4.7%

 

-1.7%

0.0%

-1.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

Single-use Products

$

190.9

 

$

184.4

 

3.6%

0.0%

3.6%

 

6.3%

 

0.1%

0.1%

0.2%

Capital Products

 

46.9

 

 

49.2

 

-4.7%

-0.2%

-4.9%

 

-2.0%

 

-7.4%

-0.5%

-7.9%

$

237.8

 

$

233.6

 

1.8%

0.0%

1.8%

 

4.7%

 

-1.7%

0.0%

-1.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

Domestic

$

134.2

 

$

128.2

 

4.7%

0.0%

4.7%

 

 

 

 

 

 

International

 

103.6

 

 

105.4

 

-1.7%

0.0%

-1.7%

 

 

 

 

 

 

$

237.8

 

$

233.6

 

1.8%

0.0%

1.8%

 

 

 

 

 

 

   

Nine Months Ended September 30,

 

% Change

 

Domestic

International

2020

 

2019

As
Reported

Impact
of
Foreign
Currency

Constant
Currency

 

As
Reported

 

As
Reported

Impact
of
Foreign
Currency

Constant
Currency

Orthopedic Surgery

$

261.9

 

$

339.5

 

-22.8%

1.2%

-21.6%

 

-25.8%

 

-21.0%

2.0%

-19.0%

General Surgery

 

347.7

 

 

350.7

 

-0.9%

0.4%

-0.5%

 

0.0%

 

-2.9%

1.2%

-1.7%

$

609.6

 

$

690.2

 

-11.7%

0.9%

-10.8%

 

-9.0%

 

-14.8%

1.7%

-13.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

Single-use Products

$

497.1

 

$

547.0

 

-9.1%

0.9%

-8.2%

 

-5.5%

 

-13.6%

1.9%

-11.7%

Capital Products

 

112.5

 

 

143.2

 

-21.5%

0.7%

-20.8%

 

-24.4%

 

-18.8%

1.4%

-17.4%

$

609.6

 

$

690.2

 

-11.7%

0.9%

-10.8%

 

-9.0%

 

-14.8%

1.7%

-13.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

Domestic

$

340.5

 

$

374.1

 

-9.0%

0.0%

-9.0%

 

 

 

 

 

 

International

 

269.1

 

 

316.1

 

-14.8%

1.7%

-13.1%

 

 

 

 

 

 

$

609.6

 

$

690.2

 

-11.7%

0.9%

-10.8%

 

 

 

 

 

 

Reconciliation of Reported Net Income to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

 

Three Months Ended September 30, 2020

 

Gross Profit

Selling &
Administrative
Expense

Operating
Income

Interest
Expense

Other
Expense

Tax
Expense/
(Benefit)

Effective
Tax Rate

Net
Income

Diluted
EPS

 

As reported

$

133,698

$

94,380

$

29,382

$

11,943

$

89

$

10,500

60.5%

$

6,850

$

0.23

 

% of sales

 

56.2%

 

39.7%

 

12.4%

 

Restructuring and related costs (1)

 

-

 

(1,009)

 

1,009

 

-

 

-

 

(87)

 

1,096

 

0.04

 

Acquisition and integration costs (2)

 

796

 

-

 

796

 

-

 

-

 

(366)

 

1,162

 

0.04

 

Manufacturing consolidation costs (3)

 

606

 

-

 

606

 

-

 

-

 

(352)

 

958

 

0.03

 

$

135,100

$

93,371

$

31,793

$

11,943

$

89

$

9,695

 

$

10,066

$

0.34

 

Adjusted gross profit %

 

56.8%

 

Amortization(4)

$

1,500

 

(6,992)

 

8,492

 

(3,439)

 

-

 

(3,980)

 

15,911

 

0.54

 

Adjusted net income

$

86,379

$

40,285

$

8,504

$

89

$

5,715

18.0%

$

25,977

$

0.88

 

% of sales

 

 

36.3%

 

16.9%

 

 

 

Three Months Ended September 30, 2019

 

 

Gross Profit

Selling &
Administrative
Expense

Operating
Income

Interest
Expense

Other
Expense

Tax
Expense

Effective
Tax Rate

Net
Income

Diluted
EPS

 

As reported

$

130,111

$

98,187

$

20,939

$

11,174

$

321

$

2,474

26.2%

$

6,970

$

0.23

 

% of sales

 

55.7%

 

42.0%

 

9.0%

 

Acquisition and integration costs (2)

 

171

 

(1,490)

 

1,661

 

-

 

-

 

290

 

1,371

 

0.05

 

Manufacturing consolidation costs (3)

 

1,430

 

-

 

1,430

 

-

 

-

 

249

 

1,181

 

0.04

 

 

$

131,712

$

96,697

$

24,030

$

11,174

$

321

$

3,013

 

$

9,522

$

0.32

 

Adjusted gross profit %

 

56.4%

 

Amortization(4)

$

1,500

 

(6,841)

 

8,341

 

(3,183)

 

-

 

2,808

 

8,716

 

0.30

 

Adjusted net income

$

89,856

$

32,371

$

7,991

$

321

$

5,821

24.2%

$

18,238

$

0.62

 

% of sales

 

38.5%

 

13.9%

 

Diluted shares

 

29,792

 

In-the-money portion of convertible notes(5)

 

(204)

 

Diluted shares, as adjusted

 

29,588

 

(1) In 2020, the Company incurred costs related to restructuring of the Orthopedic sales force consisting primarily of termination payments to distributors made in exchange for ongoing assistance to transition to employee-based sales representatives.

(2) In 2020, the Company incurred inventory adjustments associated with a prior acquisition. In 2019, the Company incurred inventory adjustments, consulting fees, legal fees, severance and integration related costs associated with the acquisition of Buffalo Filter, LLC.

(3) In 2020 and 2019, the Company incurred costs related to the consolidation of certain manufacturing operations. These costs related to winding down operations at certain locations and moving production lines to other facilities.

(4) Includes amortization of intangible assets, deferred financing fees and debt discount.

(5) In Q3 2019, the Company’s average share price exceeded the conversion price of its 2.625% convertible notes due in 2024 (the "Notes"). Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible note hedge transactions.

Reconciliation of Reported Net Income (Loss) to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

 

 

Nine Months Ended September 30, 2020

 

Gross
Profit

Selling &
Administrative
Expense

Operating
Income

Interest
Expense

Other
Expense

Tax
Expense

Effective
Tax Rate

Net
Income
(Loss)

Diluted
EPS

As reported

$

324,786

$

274,721

$

21,309

$

32,938

$

266

$

2,728

-22.9%

$

(14,623)

$

(0.51)

% of sales

 

53.3%

 

45.1%

 

3.5%

Plant underutilization costs (1)

 

6,586

 

-

 

6,586

 

-

 

-

 

739

 

5,847

 

0.20

Product rationalization costs (2)

 

2,169

 

(2,095)

 

4,264

 

-

 

-

 

460

 

3,804

 

0.13

Restructuring and related costs (3)

 

1,087

 

(3,133)

 

4,220

 

-

 

-

 

259

 

3,961

 

0.14

Acquisition and integration costs (4)

 

2,253

 

(1,192)

 

3,445

 

-

 

-

 

356

 

3,089

 

0.11

Manufacturing consolidation costs (5)

 

3,993

 

-

 

3,993

 

-

 

-

 

485

 

3,508

 

0.12

$

340,874

$

268,301

$

43,817

$

32,938

$

266

$

5,027

 

$

5,586

$

0.19

Adjusted gross profit %

 

55.9%

Amortization(6)

$

4,500

 

(20,947)

 

25,447

 

(9,936)

 

-

 

1,795

 

33,588

 

1.14

Adjusted net income

$

247,354

$

69,264

$

23,002

$

266

$

6,822

14.8%

$

39,174

$

1.33

% of sales

 

 

40.6%

 

11.4%

 

 

 

 

 

Diluted shares, as reported

 

28,529

Effect of dilutive shares assuming net earnings(7)

 

859

Diluted shares, as adjusted

 

29,388

 

Nine Months Ended September 30, 2019

Gross
Profit

Selling &
Administrative
Expense

Operating
Income

Interest
Expense

Other
Expense

Tax
Expense

Effective
Tax Rate

Net
Income

Diluted
EPS

As reported

$

382,740

$

298,140

$

51,234

$

32,382

$

4,867

$

299

2.1%

$

13,686

$

0.47

% of sales

 

55.5%

 

43.2%

 

7.4%

Acquisition and integration costs (4)

 

1,335

 

(11,196)

 

12,531

 

-

 

-

 

3,473

 

9,058

 

0.31

Manufacturing consolidation costs (5)

 

1,430

 

-

 

1,430

 

-

 

-

 

249

 

1,181

 

0.04

Debt refinancing costs (8)

 

-

 

-

 

-

 

-

 

(3,904)

 

1,149

 

2,755

 

0.09

 

$

385,505

$

286,944

$

65,195

$

32,382

$

963

$

5,170

 

$

26,680

$

0.91

Adjusted gross profit %

 

55.9%

Amortization(6)

$

4,500

 

(19,436)

 

23,936

 

(8,573)

 

-

 

8,056

 

 

24,453

 

0.83

Adjusted net income

$

267,508

$

89,131

$

23,809

$

963

$

13,226

20.6%

$

51,133

$

1.74

% of sales

 

38.8%

 

12.9%

(1) In 2020, the Company incurred a charge related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic.

(2) In 2020, the Company performed an analysis of product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings resulting in a charge to cost of sales. The Company also wrote-off related field inventory used for customer demonstration and evaluation of the discontinued products to selling and administrative expense.

(3) In 2020, the Company incurred restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic. In 2020, the Company also incurred costs related to restructuring of the Orthopedic sales force consisting primarily of termination payments to distributors made in exchange for ongoing assistance to transition to employee-based sales representatives.

(4) In 2020, the Company incurred inventory adjustments associated with a prior acquisition and severance and integration costs mainly related to the Buffalo Filter, LLC acquisition. In 2019, the Company incurred inventory adjustments, investment banking fees, consulting fees, legal fees, severance and integration related costs associated with the acquisition of Buffalo Filter, LLC.

(5) In 2020 and 2019, the Company incurred costs related to the consolidation of certain manufacturing operations. These costs related to winding down operations at certain locations and moving production lines to other facilities.

(6) Includes amortization of intangible assets, deferred financing fees and debt discount.

(7) Diluted share count used in Diluted EPS, as adjusted, for the nine months ended September 30, 2020 adjusts for shares assuming net earnings.

(8) In 2019, in conjunction with the acquisition of Buffalo Filter, LLC, the Company refinanced its existing credit facility and incurred one-time fees associated with an agreement between the Company and JP Morgan Chase Bank, N.A., as well as costs associated with the early extinguishment of debt.

Reconciliation of Reported Net Income (Loss) to EBITDA & Adjusted EBITDA

(in thousands, unaudited)

 

 

Three Months Ended

 

Nine Months Ended

 

September 30,

 

September 30,

 

2020

2019

 

2020

2019

 

 

 

 

 

 

Net income (loss)

$

6,850

$

6,970

 

$

(14,623)

$

13,686

Provision from income taxes

 

10,500

 

2,474

 

 

2,728

 

299

Interest expense

 

11,943

 

11,174

 

 

32,938

 

32,382

Depreciation

 

4,383

 

5,258

 

 

13,617

 

14,225

Amortization

 

13,580

 

13,377

 

 

40,973

 

38,837

EBITDA

$

47,256

$

39,253

 

$

75,633

$

99,429

 

 

 

 

 

 

Stock based compensation

 

3,532

 

3,008

 

 

10,119

 

8,819

Plant underutilization costs

 

-

 

-

 

 

6,586

 

-

Product rationalization costs

 

-

 

-

 

 

4,264

 

-

Restructuring and related costs

 

1,009

 

-

 

 

4,220

 

-

Manufacturing consolidation costs

 

606

 

1,430

 

 

3,993

 

1,430

Acquisition and integration costs

 

796

 

1,661

 

 

3,445

 

12,531

Debt refinancing costs

 

-

 

-

 

 

-

 

3,904

Adjusted EBITDA

$

53,199

$

45,352

 

$

108,260

$

126,113

 

 

 

 

 

 

 

 

 

 

 

 

EBITDA Margin

 

 

 

 

 

EBITDA

 

19.9%

 

16.8%

 

 

12.4%

 

14.4%

Adjusted EBITDA

 

22.4%

 

19.4%

 

 

17.8%

 

18.3%

About CONMED Corporation

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today’s conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2019, and listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted other expense; adjusted income tax expense (benefit); adjusted effective income tax rate; adjusted net income, adjusted diluted shares and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, other expense, income tax expense, effective income tax rate, net income (loss), diluted shares and diluted net earnings (loss) per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.


Contacts

CONMED Corporation
Todd Garner
Chief Financial Officer
315-624-3317
ToddGarner@conmed.com